Prima BioMed (NASDAQ:IMMP) and Apogee Therapeutics (NASDAQ:APGE) Head to Head Survey

Prima BioMed (NASDAQ:IMMP) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Prima BioMed and Apogee Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1	3	0	0	1.75
Apogee Therapeutics	1	4	11	2	2.78

Prima BioMed currently has a consensus price target of $5.50, suggesting a potential upside of 1,222.12%. Apogee Therapeutics has a consensus price target of $113.63, suggesting a potential upside of 44.36%. Given Prima BioMed’s higher probable upside, analysts plainly believe Prima BioMed is more favorable than Apogee Therapeutics.

Institutional & Insider Ownership

2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 3.1% of Prima BioMed shares are held by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Prima BioMed has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500.

Profitability

This table compares Prima BioMed and Apogee Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Apogee Therapeutics	N/A	-32.64%	-31.25%

Valuation and Earnings

This table compares Prima BioMed and Apogee Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$6.69 million	9.16	-$39.78 million	N/A	N/A
Apogee Therapeutics	N/A	N/A	-$255.84 million	($4.33)	-18.18

Prima BioMed has higher revenue and earnings than Apogee Therapeutics.

Summary

Prima BioMed beats Apogee Therapeutics on 6 of the 11 factors compared between the two stocks.

About Prima BioMed

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

About Apogee Therapeutics

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.